Actinogen Medical Limited (ACW.XA)
| Previous close | 0.0800 |
| Open | 0.0810 |
| Bid | 0.0830 x N/A |
| Ask | 0.0850 x N/A |
| Day's range | 0.0790 - 0.0860 |
| 52-week range | 0.0150 - 0.0990 |
| Volume | |
| Avg. volume | 2,771,607 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0050 |
| Earnings date | 22 Aug 2024 - 26 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePositive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
Actinogen Medical Limited (ASX:ACW) announces the peer-reviewed publication of its phase 2a biomarker trial entitled "Plasma pTau181 Predicts Clinical Progression In A Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem for Mild Alzheimer's Disease" in the 100th edition of the Journal of Alzheimer's Disease.
- PR Newswire
Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial
Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept, placebo-controlled, parallel group trial with a six-week treatment period and four weeks of follow up.
- PR Newswire
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
Actinogen Medical Limited (ASX: ACW) announces that the first patient has been randomized and treated in the XanaMIA phase 2b clinical trial in patients with biomarker-positive mild to moderate Alzheimer's disease (AD). This represents the culmination of the site and screening setup phase of the trial when patient pre-screening for elevated levels of the pTau blood biomarker commenced at multiple clinical sites.
